Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 17;14(3):9429.
doi: 10.4081/dr.2022.9429. eCollection 2022 Sep 14.

The effectiveness of erysipelas prophylaxis depends on the cumulative dose of benzathine penicillin G

Agnieszka Bednarska  1   2 , Iwona Sosińska-Bryła  2 , Paweł Grąbczewski  2 , Regina Podlasin  2 , Marcin Paciorek  1   2 , Dominik Bursa  1   2 , Małgorzata Hackiewicz  2 , Michał Makowiecki  2 , Andrzej Horban  1   2
Affiliations

The effectiveness of erysipelas prophylaxis depends on the cumulative dose of benzathine penicillin G

Agnieszka Bednarska et al. Dermatol Reports. .

Abstract

Erysipelas is an acute infection due to S. pyogenes and is characterized by a high risk of relapses. The number of patients suffering from one or more recurrences varied depending on the study and accounted for between 16% and 47% of the total number of those affected. Antibiotic prophylaxis with the use of penicillin can reduce the risk of recurrence by 47%. A number of 873 patients with erysipelas treated at the Hospital for Infectious Diseases in Warsaw from 2010 to 2018 was enrolled in the study. Benzathine-penicillin G was given intramuscularly at a dose of 1.2 MU or 2.4 MU or 3.6 MU. The earliest moment that prophylactic treatment was administered was the first episode of erysipelas recurrence. The decision to administer the antibiotic and the dose to use was discretionally made by the examining physician. Altogether 104 (11.9%) persons experienced at least one episode of erysipelas recurrence during the study period. A total of 2976 doses of benzathine- penicillin G (BP) were administered. The most common dose was that of 2.4 MU (2380, 80%). The dose of 1.2 MU was given 567 times (19%). The highest dose, i.e. 3.6 MU, was administered to only 5 patients (8 applications, 0.2%). No effect was shown by either the number of benzathine- penicillin G administered doses (p=0.07) or the median dose (p=0.65), whereas patients without relapse received a statistically higher cumulative dose of the antibiotic (p=0.047). Age was a risk factor of recurrence only in the group of diabetic patients (p=0.03). Benzathine penicillin G given in an appropriate cumulative dose is effective in preventing erysipelas recurrence.

Keywords: Benzathine penicillin G; Cumulative dose; Erysipelas; Recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no potential conflict of interest.

Figures

Figure 1.
Figure 1.
Age as a risk factor in the group of diabetic patients.
Figure 2.
Figure 2.
Impact of cumulative dose of benzathine penicillin G on the risk of erysipelas recurrences.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Chlebicki MP, Oh CC. Recurrent Cellulitis: Risk, Factors, Etiology, Pathogenesis and Treatment. Curr Infect Dis Rep 2014;16:422. - PubMed
    1. Kasper DL, Fauci AS. Harrison's Infectious Diseases. 3rd ed. McGraw- Hill Education; 2017.
    1. Leclerc S, Teixeira A, Mahe E, et al. . Recurrent Erysipelas: 47 Cases. Dermatology 2007;2014:52-7. - PubMed
    1. Rob F, Hercegova J. Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas: a retrospective study of 132 patients. J Dermatolog Treat 2018;29:39-4. - PubMed
    1. Dalal A, Eskin-Schwartz M, Mimouni D, et al. . Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database Syst Rev 2017;6:CD009758. - PMC - PubMed